Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alatrofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | RARB | P10826 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alatrofloxacin SCHEMBL7616277 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL140567 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7618000 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7101443 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL6848316 | 0.97 | EPHA2 (0.65) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL28214885 | 0.97 | EPHA2 (0.75) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL29389843 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL41134 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL8186971 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL9735079 | 0.95 | EPHA2 (0.74) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956956-A | Surgical system and method of use | 美敦力公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-116583312-A | Surgical system and method of use | 美敦力公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116583310-A | Surgical system and method of use | 美敦力公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116251176-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-116077629-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115845035-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115845034-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115671268-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115671027-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115671269-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115671267-A | Subcutaneous antibiotic pharmaceutical composition | 上海宝济药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113081991-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-109431965-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114206322-A | Carrier-based formulations and related methods | 瑞必治公司 | 2022-03-18 | — | — | CN | disclosed |